Abstract:Abstract Background Interleukin-33 (IL-33) is an effective inducer of pro-inflammatory cytokines regulating innate and adaptive immunity. Inflammation could be a double-edged sword, promoting or inhibiting tumour growth. To date, the roles and mechanisms of IL-33 in tumours remain controversial. Here, we examined the effect of exogenous IL-33 on the biological characteristics of hepatocellular carcinoma (HCC) and the possible mechanism of action. Methods In this study, IL-33 expression in the tissues of 69 HCC patients was detected and its relationship with prognosis was evaluated. After establishing a mouse HCC model and IL-33 treatment operation, the infiltration of splenic myeloid-derived suppressor (MDSCs), dendritic (DCs), regulatory T, and natural killer (NK) cells was detected by flow cytometry analysis, and the vascular density of the tumour tissues was detected by immunohistochemistry to reveal the mechanism of IL-33 in HCC proliferation. Finally, the Cancer Genome Atlas database was used to analyse Gene Ontology terms the and Kyoto Encyclopaedia of Genes and Genomes pathway. Moreover, the chi-square test, two-tailed unpaired Student’s t -test, and multiple t- tests were performed using SPSS version 23.0 and GraphPad Prism 8.0 software. Results The IL-33 expression level was negatively correlated with the overall survival of HCC patients, suggesting its potential clinical significance in the prognosis of HCC. We found that systemic IL-33 administration significantly promoted the tumour size in vivo. Furthermore, the IL-33-treated mice presented decreased frequencies of tumouricidal NK and CD69 + CD8 + T cells. After IL-33 treatment, the incidence of monocytic MDSCs and conventional DCs increased, while that of granulocytic MDSCs decreased. Moreover, IL-33 promoted the formation of intracellular neovascularization. Therefore, IL-33 accelerated HCC progression by increasing the accumulation of immunosuppressive cells and neovascularization formation. Finally, we found that the transcription of IL-33 was closely related to the PI3K-Akt and MAPK pathways in Gene Set Enrichment Analysis plots, which were involved in the tumourigenesis and pathogenesis of HCC. Conclusions Taken together, IL-33 may be a key tumour promoter of HCC proliferation and tumourigenicity, an important mediator, and a potential therapeutic target for regulating HCC progression.

The Contradictory Role of Interleukin-33 in Immune Cells and Tumor Immunity.

Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy

Cmar_a_262745 7527..7537

Toll-like Receptor 3 and Tumor Immunity

Interleukin 33 in Tumor Microenvironment is Crucial for the Accumulation and Function of Myeloid-Derived Suppressor Cells

Immune Function of Interleukin-33 and Its Relation to Human Diseases

Dual Immune Regulatory Roles of Interleukin-33 in Pathological Conditions

Role of IL-33 in Transplant Biology

Dual role of interferons in tumor immunology

[Progress on Interleukin-27 in Tumor Immunity].

The Controversial Role of IL-33 in Lung Cancer

Immunomodulation of Interleukin-34 and Its Potential Significance As a Disease Biomarker and Therapeutic Target

IL-33/ST2 as a potential target for tumor immunotherapy

Unveiling the multifaceted antitumor effects of interleukin 33

The Role of IL-33-Dependent Inflammation in the Tumor Microenvironment

Exogenous IL-33 promotes tumor immunity via macroscopic regulation of ILC2s

Interleukin‐33 Activates and Recruits Natural Killer Cells to Inhibit Pulmonary Metastatic Cancer Development

Interleukin-33 in health and disease

Novel insights into IL-37: an anti-inflammatory cytokine with emerging roles in anti-cancer process

Abstract 2700: Therapeutic IL-33 enhances the antigen presentation function of ILC2s to exert anti-tumor immune activity

Exogenous interleukin-33 promotes hepatocellular carcinoma growth by remodelling the tumour microenvironment